Navigation Links
Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
Date:9/5/2007

ults, Stimuvax has entered its Phase III development and the START (Stimulating Targeted Antigenic Responses to NSCLC) trial is currently open for enrollment. The START trial is being conducted by Merck KGaA of Darmstadt, Germany, which has licensed worldwide development and commercialization rights to Stimuvax from Biomira. Stimuvax is being developed in Europe by Merck KGaA and in the United States by its affiliate, EMD Serono Inc.

"Patients with unresectable stage III non-small cell lung cancer have significant unmet medical need, and the START study is the first Phase III program to evaluate a therapeutic cancer vaccine in this population," said Dr. Robert L. Kirkman, MD, President and Chief Executive Officer of Biomira. "If these survival results are statistically confirmed in the Phase III trial, Stimuvax has the potential to become an important tool in the treatment of lung cancer."

According to the American Cancer Society, lung cancer is the leading cause of cancer-related deaths in both men and women worldwide, with approximately 80% of cases classified as NSCLC. Current survival rates for NSCLC are low, with only 16% of patients alive five years post-diagnosis. Unfortunately for most patients, current treatments provide limited success. Stimuvax is an innovative cancer vaccine designed to stimulate the body's immune system to identify and destroy cancer cells expressing MUC1, a protein antigen that is widely expressed on common cancers including lung, breast and colorectal.

About the Phase II Trial

171 patients with ECOG 0-2 stage IIIB/IV NSCLC with stable or responding disease after any first-line chemotherapy with or without radiotherapy were randomized to receive Stimuvax plus BSC or BSC alone. Patients were stratified by stage of disease (IIIB LR or stage IIIB with malignant pleural effusion, and stage IV). Patients in the Stimuvax arm received a single intravenous dose of cyclophosphamide 300mg/m2 followed by 8 weekly subcutane
'/>"/>

SOURCE Biomira Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Protocol for RNA Isolation Using TRIzol Reagent with Phase Lock Gel-Heavy
2. Protocol for RNA Isolation Using TRIzol Reagent with Phase Lock Gel-Heavy
3. Easy preparation of total RNA from cultured cells with TRIzol and Eppendorf Phase Lock Gel
4. Identification of cells in S phase using the Cell Proliferation Fluorescence Kit and IN Cell Analyzer 1000
5. Direct Monitoring of Solid-Phase Peptide Synthesis by MALDI-TOF MS
6. Separation and Quantitation of R and S Enantiomers using Normal Phase Chromatography on an API 3000 LC/MS/MS System
7. Identification of Phase I and Phase II Metabolites of Buspirone on the Q TRAP LC/MS/MS System
8. Strategies to Identify and Confirm Phase I Metabolites of Glyburide Using the 4000 Q TRAP System
9. ANALYSIS OF AMINO ACIDS BY REVERSED PHASE CHROMATOGRAPHY WITH PRECOLUMN DERIVATISATION AND UV/VISIBLE DETECTION
10. Novel Bonding Chemistry Imparts Enhanced Polar Selectivity to TSK-GEL ODS-100V Reversed Phase Columns
11. Mobile Phase Optimization for the Analysis of an Antibody-Based Fusion Protein and Aggregates using a TSKgel Super SW3000 Size-Exclusion Column
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... a way to create a highly sensitive chemical sensor ... imperfections have unique electronic properties that the researchers were ... molecules by 300 times. , The study is available ... . , Amin Salehi- Khojin, asst professor of mechanical ... graduate student and Bijandra Kumar, post doc where they ...
(Date:9/22/2014)... This is a professional and in-depth ... industry in Global and China. The report provides ... and industry chain structure. Global market analysis and Chinese ... history, developments, trends and competitive landscape of the market. ... also offered. , The report also focuses on development ...
(Date:9/22/2014)... Topical BioMedics, Inc., is celebrating 20 ... their suffering, restoring hope an quality of life and ... possible because of the innovative cellular biomedicines research that ... reality. , The company was founded in 1994 ... (president, chief of research, and Topricin inventor), Aurora Paradise ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 ... desire to stay young has groomed and nurtured ... industry worldwide. Growing emphasis on appearance maintenance is ... is a neurotoxic protein obtained from the bacterium, ... resulting in muscle relaxation. With cosmetic indications for ...
Breaking Biology Technology:Graphene imperfections key to creating hypersensitive 'electronic nose' 2m-Phenylenediamine Industry: mPDA Global & China Trend Analysis Now Available at ReportsnReports.com 2m-Phenylenediamine Industry: mPDA Global & China Trend Analysis Now Available at ReportsnReports.com 3Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 3Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 4Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 5Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 6Strong Demand for Non-Invasive Cosmetic Procedures Drives the Global Botulinum Toxin Market, According to New Report by Global Industry Analysts, Inc. 2Strong Demand for Non-Invasive Cosmetic Procedures Drives the Global Botulinum Toxin Market, According to New Report by Global Industry Analysts, Inc. 3
... Austria, May 27 The atherosclerosis vaccine,development program ... the,EU,s EUROTRANS-BIO call. The respective project is being ... GmbH. The aim of,atherosclerosis vaccination is to increase ... in the blood and thus reduce the occurrence ...
... Efficiency and Manage Quality at New LIFE Nutrition Factory ... (NYSE: HON ) today announced that it ... manufacturer of healthcare products, to provide process control solutions ... and infusion therapy solutions. The Leading Infusion Factory Europe ...
... SEATTLE, May 27 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ... previously announced sale of 3,878,993 shares of its common stock ... for gross proceeds of approximately $11.1 million on May 26, ... unit (each unit consisting of one share and a warrant ...
Cached Biology Technology:AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support 2AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support 3Honeywell to Help B. Braun Healthcare Company Double Manufacturing Capacity of Life-Critical Products 2Honeywell to Help B. Braun Healthcare Company Double Manufacturing Capacity of Life-Critical Products 3Honeywell to Help B. Braun Healthcare Company Double Manufacturing Capacity of Life-Critical Products 4Oncothyreon announces closing of $11.1 million registered direct financing 2
(Date:9/23/2014)... consumption could be as good for your mental as ... conducted by the University of Warwick,s Medical School using ... by BMJ Open focused on mental wellbeing ... consistently associated with an individual,s fruit and vegetable consumption. ... five or more portions of fruit and vegetables a ...
(Date:9/23/2014)... including humans, have parasitic DNA fragments called "jumping genes" ... in the process. And that phenomenon can result in ... University of Rochester now report that the "jumping genes" ... a multi-function protein stops keeping them in check in ... a study published today in Nature Communications , ...
(Date:9/22/2014)... STATION The smell of cut grass in recent ... signalling distress, but new research says the aroma also ... is need for protection, the plant signals the environment ... recognized as a feeding queue for parasitic wasps to ... lay eggs in the pest insect," said Dr. Michael ...
Breaking Biology News(10 mins):Eating five a day may keep the blues away 2A multi-function protein is key to stopping genomic parasites from 'jumping' 2Mown grass smell sends SOS for help in resisting insect attacks, researchers say 2Mown grass smell sends SOS for help in resisting insect attacks, researchers say 3
... This release is available in Spanish . ... Medical Research (CIMA) of the University of Navarra has identified ... enzyme is involved in the accumulation of fibrous tissues in ... of heart functions. The research project, published in the ...
... April 21 More than 3,200 items of ... be displayed during the 2009 Force Protection Equipment ... VA, and Marine Corps Base, Quantico, VA, during ... of Defense, personnel with physical security responsibilities in ...
... losses and the environmental impact caused by invasive species ... alone. An example of this is the zebra mussel, ... to a New York Sea Grant report. In ... species, the armored catfish, or plecostomus, in the Infiernillo ...
Cached Biology News:Researchers identify a molecule that increases the risk of cardiac insufficiency 2Combating Terrorism with Commercial Technology: 2009 Force Protection Equipment Demonstration 2North America works to halt invasive species 2
Edited by D.M. Gersten (1996) Provides comprehensive descriptions of the techniques available for analytical gel electrophoresis of proteins and offers clear step-by-step protocols for all of the m...
...
All serum is collected from U.S.D.A. fryers and broilers. Pricing: $15/unit for 1 - 10 units; $12/unit for 11 - 50 units...
RAT ANTI MOUSE TCR V BETA 7:RPE Immunogen: T-cell lymphoma TK1...
Biology Products: